Anticytokine autoantibodies in a patient with a heterozygous NFKB2 mutation - 05/04/18
Doi : 10.1016/j.jaci.2017.11.014
Kesava A. Ramakrishnan, MD a, ∗, William Rae, MRCP b, c, ∗, Gabriela Barcenas-Morales, PhD d, e, ∗, Yifang Gao, PhD f, Reuben J. Pengelly, PhD a, Sanjay V. Patel, MRCPCH g, Dinakantha S. Kumararatne, MD, FRCPath d, Sarah Ennis, PhD a, Rainer Döffinger, FRCPath, PhD d, h, ∗, Saul N. Faust, FRCPCH, PhD a, b, g, ∗ 
, Anthony P. Williams, FRCPath, PhD a, c, f, i, ∗
, Anthony P. Williams, FRCPath, PhD a, c, f, i, ∗ a Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, United Kingdom
b Southampton NIHR Wellcome Trust Clinical Research Facility and NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
c Department of Allergy, Asthma and Clinical Immunology, University Hospital Southampton, Southampton, United Kingdom
d Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
e Laboratorio de Inmunologia, Facultad de Estudios Superior, Universidad Autonoma de Mexico, Cuautitlan-Izcalli, Edo de Mexico, Mexico
f CRUK NIHR Experimental Cancer Medicine Centre, Southampton, United Kingdom
g Department of Paediatric Immunology and Infectious Diseases, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
h National Institute of Health Research, Cambridge Biomedical Research Centre, Cambridge, United Kingdom
i WISH Laboratory University Hospital Southampton NHS Foundation Trust, University of Southampton, Southampton, United Kingdom
| Y.G. and A.P.W. were supported by Cancer Research UK and the National Institute for Health Research (NIHR) Experimental Cancer Medicine Centre, Southampton. K.A.R., W.R., S.V.P., and S.N.F. received support from the Southampton NIHR Wellcome Trust Clinical Research Facility. G.B.-M. was supported by grants from Universidad Nacional Autónoma de México – Dirección General de Asuntos del Personal Académico - Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica (UNAM-DGAPA-PAPIIT; grant nos. IN220815 and PIAPI-1642). R.D. was supported by the NIHR/Cambridge Biomedical Research Centre. |
|
| Disclosure of potential conflict of interest: S. N. Faust's institution received consultancy fees from AstraZeneca, Cubist, Merck, and Pulmizime and grants from Pfizer, Sanofi, GSK, Novartis, Alios, Cubist, and Merck for other work. D. S. Kumararatne received consultancy fees from Shire Pharmaceticals and support for travel from CSL Behring for this work and is employed by University Hospital Cambridge. W. Rae received consultancy fees from Baxalta and travel fees from Shire Plc; his institution received grants from BioCryst Pharmaceuticals for other works. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2017
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 141 - N° 4
P. 1479 - avril 2018 Retour au numéro
Article précédent
- Thymic stromal lymphopoietin does not activate human basophils
- Nina Salabert-Le Guen, Caroline Hémont, Agathe Delbove, Caroline Poli, Cécile Braudeau, Aurélie Fantou, Karine Amouriaux, Gaelle Bériou, Jérôme C. Martin, Luc Colas, Vassili Soumelis, Régis Josien
- Early-onset childhood atopic dermatitis is related to NLRP2 repression
- Loreen Thürmann, Konrad Grützmann, Matthias Klös, Matthias Bieg, Marcus Winter, Tobias Polte, Tobias Bauer, Matthias Schick, Melanie Bewerunge-Hudler, Stefan Röder, Mario Bauer, Dirk K. Wissenbach, Ulrich Sack, Dieter Weichenhan, Oliver Mücke, Christoph Plass, Michael Borte, Martin von Bergen, Irina Lehmann, Roland Eils, Saskia Trump
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?